Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 5
Author: Motilal Oswal

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	12 Sep 2025	Sun Pharmaceutical	Consensus Share Price Target	1616.60	1930.16	-	19.40	buy	pdf Detailed Estimates
	02 Nov 2023	Sun Pharmaceutical	Motilal Oswal Target	1616.60	1310.00	1132.85 (42.70%)	Target met	Buy	pdf post cache	Broker Report Superior execution drives broad-based revenue growth Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	02 Nov 2023	Sun Pharmaceutical	BOB Capital Markets Ltd. Target	1616.60	1200.00	1132.85 (42.70%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): Healthy quarter; better mix supports gross margin BOB Capital Markets Ltd. Q2 revenue/PAT grew 11%/5% YoY to Rs 122bn/Rs 24bn, largely in line with consensus pdf Copy Link Share on Share on Share on Share on Alert
	02 Nov 2023	Sun Pharmaceutical	ICICI Securities Limited Target	1616.60	1210.00	1132.85 (42.70%)	Target met	Accumulate	pdf post cache	Broker Report Branded drives growth; overheads dampen margins ICICI Securities Limited Sun Pharma (Sun)’s Q2FY24 performance was lower than our expectation (though in line with Street) due to higher overheads and lower sales of gRevlimid. Traction in branded generics business across India, emerging markets and RoW coupled with specialty business in US led to 11.3% growth in revenue. pdf Copy Link Share on Share on Share on Share on Alert
	12 Sep 2023	Sun Pharmaceutical	Geojit BNP Paribas Target	1616.60	1255.00	1145.25 (41.16%)	Target met	Buy	pdf post cache	Broker Report SUN PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	04 Aug 2023	Sun Pharmaceutical	ICICI Securities Limited Reco Target	1616.60	1255.00	1138.95 (41.94%)	Target met	Accumulate	pdf post cache	Broker Report US generics drives the Q1 show; launched 10 new products ICICI Securities Limited Sun Pharmaceutical’s (Sun) Q1FY24 performance was driven by better sales of generics in the US, while specialty growth took a back seat. US generics’ business ex-Taro rose 10% QoQ. Impact of lower sales of Levulan in Q1 was largely offset by higher sales of gRevlimid (estimated at USD 35-40mn) and helped Sun report an in-line result. pdf Copy Link Share on Share on Share on Share on Alert
	03 Aug 2023	Sun Pharmaceutical	Prabhudas Lilladhar Target	1616.60	1265.00	1141.00 (41.68%)	Target met	Buy	pdf post cache	Broker Report SUN PHARMACEUTICAL I Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	03 Aug 2023	Sun Pharmaceutical	BOB Capital Markets Ltd. Reco Target	1616.60	1160.00	1141.00 (41.68%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): gRevlimid buoys performance; upside capped cut to HOLD BOB Capital Markets Ltd. Q1 revenue/EBITDA beat consensus by 2%/11%, but reported PAT missed estimates by 6% due to exceptional items pdf Copy Link Share on Share on Share on Share on Alert
	02 Aug 2023	Sun Pharmaceutical	IDBI Capital	1616.60	1230.00	1135.25 (42.40%)	Target met	Buy	pdf post cache	Broker Report Technical pick update 01 - SUN PHARMA IDBI Capital pdf Copy Link Share on Share on Share on Share on Alert
	07 Jul 2023	Sun Pharmaceutical	IDBI Capital	1616.60	1230.00	1035.70 (56.09%)	Target met	Buy	pdf post cache	Broker Report TECHNICAL PICK: SUN PHARMA IDBI Capital pdf Copy Link Share on Share on Share on Share on Alert
	14 Jun 2023	Sun Pharmaceutical	Motilal Oswal	1616.60	1160.00	986.70 (63.84%)	Target met	Buy	pdf post cache	Broker Report Promising growth outlook for Specialty brands Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
more loading

Near 52W Low of ₹1553.05

Sun Pharmaceutical Industries Ltd. share price target

Sun Pharmaceutical Industries Ltd. has an average share price target of 2050.25. The consensus estimate represents an upside of 26.82% from the last price of 1616.60. View 14 reports from 8 analysts offering long-term price targets for Sun Pharmaceutical Industries Ltd..

Superior execution drives broad-based revenue growth

Sun Pharma (HOLD): Healthy quarter; better mix supports gross margin

Branded drives growth; overheads dampen margins

SUN PHARMA

US generics drives the Q1 show; launched 10 new products

SUN PHARMACEUTICAL I

Sun Pharma (HOLD): gRevlimid buoys performance; upside capped cut to HOLD

Technical pick update 01 - SUN PHARMA

TECHNICAL PICK: SUN PHARMA

Promising growth outlook for Specialty brands

Advisor Screeners